Progress in the treatment of rheumatoid arthritis.
Pisetsky
D S
DS
Division of Rheumatology, Allergy, and Clinical Immunology, Duke University Medical Center, 1516 Durham Veterans Affairs Medical Center, Box 151G, Durham, NC 27710, USA. dpiset@acpub.duke.edu
St Clair
E W
EW
D000700:Analgesics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D000068800:Etanercept; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008727:Methotrexate / Q000627:therapeutic use; D008911:Minocycline / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use
D000700:Analgesics; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D016572:Cyclosporine; D000069285:Infliximab; D008911:Minocycline; D000077339:Leflunomide; D010396:Penicillamine; D001379:Azathioprine; D000068800:Etanercept; D008727:Methotrexate